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Abstract To examine the correlation of survivin (both
total and nuclear survivin) with clinicopathological param-
eters of esophageal squamous cell carcinoma (ESCC)
patients. Tumors and non-tumor tissues near the proximal
resection margins were resected from ESCC patients
undergone esophagectomy. Quantitative polymerase chain
reaction (qPCR) was performed to detect survivin mRNA
expression level in the 10 paired tumor and adjacent non-
tumor tissues. To confirm with the clinical situation, survivin
mRNA and protein expression were measured by qPCR and
immunoblot, respectively, in 5 ESCC cell lines and a non-
neoplastic esophageal epithelial cell line. Immunohisto-
chemistry was employed to reveal the cellular localization of
survivin in tumor tissues isolated from the 64 ESCC patients
undergone surgery alone. Up-regulation of survivin mRNA
and protein was found in 5 ESCC lines (HKESC-1, HKESC-
2, HKESC-3, HKESC-4, and SLMT-1) when compared to a
non-neoplastic esophageal epithelial cell line NE-1. In par-
ticular, HKESC-3, HKESC-4, and SLMT-1 cells demon-
strated *50-fold increase in survivin mRNA. High level of
survivin mRNA in tumor tissues when compared to non-
tumor tissues was found in 70 % (7 of 10) of clinical cases.
The increase in expression ranged from *twofold to *16-
fold. Immunohistochemistry results showed that survivin
was found at the cell nuclei in all specimens examined.
Nuclear expression of survivin was inversely associated with
the likelihood of developing nodal metastasis (p = 0.021)
and significantly associated with early-stage ESCC
(p = 0.039). Nuclear survivin could serve as a marker for
indicating disease status in ESCC patients.
Keywords Esophageal squamous cell carcinoma 
Nuclear survivin  Nodal metastasis  Pathological stage 
Biomarker
Introduction
Esophageal cancer is the eighth most prevalent cancer
worldwide and ranks sixth as the most common cause of
cancer-related deaths. Among all histological subtypes,
esophageal squamous cell carcinoma (ESCC) is the pre-
dominant type in Asia. Unfortunately, the prognosis of
ESCC is relatively poor and survival rate is low [1].
Recently, increasing number of studies has been dedicated
to identify important prognostic markers for this malig-
nancy, for which survivin is a potential one [2–8].
Survivin is a 16.5-kDa protein with 142 amino acid
residues. It is reported to be highly expressed in many types
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of cancers but rarely present in normal tissues [9]. Survivin
is one of the key players in the complex network regulating
apoptosis. It belongs to the family of the inhibitor of
apoptosis proteins (IAPs), which is a group of proteins that
counteract programmed cell death through inhibiting cas-
pase 3, 7, and 9 [10]. Five isoforms of survivin arisen from
alternative splicing have been identified so far [11–14].
Among them, the wild-type survivin is the most studied
isoform and is shown to involve in progression of various
cancers [15–17].
Based on the serial analysis of gene expression (SAGE)
study, survivin is proposed to be a promising prognostic
biomarker for tumor [18]. The prognostic value of survivin
has been reported in several studies of different cancer
types [9]. By using biochemical methods of immunohis-
tochemistry or subcellular fractionation, survivin can be
detected in cell nucleus and cytoplasm and that these two
pools of survivin are indeed functionally different [12].
Conflicting data exist regarding the cellular localization
of survivin. While most immunohistochemical studies
reporting the cytoplasmic localization of survivin [9], some
demonstrated the localization of survivin in the nucleus and
correlated with better prognosis [19, 20]. Still, limited
information is available for stating the cellular localization
of survivin in ESCC. Therefore, it is of interest to inves-
tigate the cellular localization of survivin and its potential
clinical significance in ESCC patients.
Materials and methods
Human cell lines
5 ESCC lines (HKESC-1, HKESC-2, HKESC-3, HKESC-4,
and SLMT-1) and a non-neoplastic esophageal epithelial
cell line NE-1 used in this study were established by our
team earlier [21–25]. The culture condition of these cell
lines was followed as described previously. NE-1 cells
were cultured in Keratinocyte-SFM medium (Invitrogen,
Carlsbad, CA). HKESC-1 and HKESC-4 were maintained
in minimum essential medium (MEM) medium (Invitro-
gen) with 10 % fetal bovine serum (FBS), while HKESC-2,
HKESC-3, and SLMT-1 were cultured in MEM medium
with 20 % FBS. All types of medium used in this study
were supplemented with 1 % penicillin–streptomycin.
Cultures were incubated at 37 C in a humidified atmo-
sphere containing 5 % CO2.
Clinical specimens
Sixty-four ESCC patients undergone esophagectomy
between 1997 and 2005 at Queen Mary Hospital, Hong
Kong, were recruited for this study, and the patient data
were summarized in Table 1. None of the patients received
neoadjuvant chemotherapy or radiotherapy. Consent
regarding the use of clinical specimens for this study was
obtained from Institutional Review Board of The Univer-
sity of Hong Kong/Hospital Authority Hong Kong West
Cluster (HKU/HA HKW IRB). Tumors and non-tumor
tissues near the proximal resection margins were resected.
A portion of the specimens was processed for routine
histopathological diagnosis by fixing in 10 % formalin
followed by embedding in paraffin; 5 lm sections were
prepared and stained with hematoxylin and eosin for light
Table 1 Clinical and pathological parameters of esophageal squa-
mous cell carcinoma patients
Number of cases % Median (range)
Age (years) 64 65 (40–87)
Gender
Female 17 26.6
Male 47 73.4
Smoking
Non Smoker 31 48.4
Smoker 33 51.6
Level of tumor
Upper 10 15.6
Middle 37 57.8
Lower 14 21.9
Double 3 4.7
Tumor differentiation
Poor 14 21.9
Moderate 38 59.4
Well 12 18.8
R category
R0 45 70.3
R1/R2 19 29.7
T-stage
T1 2 3.1
T2 11 17.2
T3 38 59.4
T4 13 20.3
N-stage
N0 26 40.6
N1 38 59.4
M-stage
M0 58 90.6
M1 6 9.4
Overall pathological stage
I 1 1.6
II 24 37.5
III 33 51.6
IV 6 9.4
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microscopy. These sections were examined and classified
into different grades based on the criteria of the World
Health Organization. A portion of the remaining specimens
was then frozen for long-term storage until use. The
median follow-up period of the patients is 14.1 months
(ranged from 1.2 to 90.6 months).
Quantitative polymerase chain reaction
RNA was extracted from cultured cells and clinical spec-
imens using TRIzol reagent (Invitrogen), according to
manufacturer’s instructions. Reverse transcription and
quantitative polymerase chain reaction (qPCR) were per-
formed as described [26–28]. In brief, 500 ng cDNA was
reverse transcribed into cDNA using SuperScript III First-
Strand Synthesis System for RT-PCR kit (Invitrogen),
following manufacturer’s protocol. cDNA was then sub-
jected for qPCR using Platinum Quantitative PCR Super-
Mix-UDG w/ROX (Invitrogen) and survivin-specific
primers (forward: 50-AAG GAC CAC CGC ATC TCT AC-30
and reverse: 50-CAG CTC CTT GAA GCA GAA GAA- 30),
for which this pair of primers were able to detect all splice
variants of survivin. In parallel experiment, b-actin was
used as an internal control for normalization and its specific
primers were used (forward: 50-CCA TCA TGA AGT GTG
ACG TG-30 and reverse: 50-ATC CAC ATC TGC TGG
AAG GT-30). qPCR was performed in ABI PRISM 7700
Sequence Detection System (Applied Biosystems, Carls-
bad, CA).
Immunoblot
Proteins were extracted from cultured cells using ice-
cooled Cell Lysis Buffer (Cell Signaling Technology,
Danvers, MA). 30 lg protein was resolved onto a 12 %
sodium dodecyl sulfate (SDS) polyacrylamide gel before
subjected to electro-transfer onto the polyvinylidene fluo-
ride (PVDF) membrane as described [29, 30]. After
blocking with 5 % non-fat milk at room temperature for
2 h, membranes were incubated overnight with rabbit
monoclonal antibody against survivin (Cell Signaling
Technology, clone 71G4B7E, at 1:1,500 dilution) at 4 C.
This antibody was able to recognize all isoforms of sur-
vivin. Detection of b-actin as a loading control was
achieved using b-actin antibody (Sigma-Aldrich, St Louis,
MO, USA clone AC-74, at 1:10,000 dilution). Horseradish
peroxidase (HRP)-conjugated secondary antibodies were
used for recognizing primary antibodies, and the signals
were subsequently viewed using ECL Plus Western blot-
ting reagent pack (GE Healthcare Biosciences, Piscataway,
NJ, USA) followed by autoradiography.
Immunohistochemistry
Immunohistochemistry was performed as previously
described [31–33]. Paraffin-embedded clinical sections
were deparaffinized and rehydrated in xylene and alcohol.
Antigen retrieval was performed by heating the sections
in 0.1 mol/L citrus buffer (pH 6.0) in a microwave for
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Fig. 1 High mRNA expression of survivin in esophageal squamous
cell carcinoma (ESCC) specimens. Quantitative polymerase chain
reaction (qPCR) was performed to examine the mRNA expression of
survivin in ESCC tissues and their adjacent non-tumor tissues. High
expression of survivin mRNA was found in 7 of 10 ESCC tissues. The
relative expression level of each non-tumor tissue was arbitrarily set
at 1. The fold ratio of tumor versus non-tumor tissues is indicated
above the bar for each patient. Experiment for each sample was
repeated twice
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10 min. After quenching the endogenous peroxidase
activities using 3 % hydrogen peroxide for 20 min at room
temperature, the sections were incubated with 10 % normal
goat serum for 1 h at room temperature to block the non-
specific binding sites. After that, the sections were incu-
bated with survivin antibody (1:100) at 4 C overnight.
Anti-rabbit labeled polymer-HRP provided in EnVi-
sion ? System-HRP (Dako, Glostrup, Denmark) was used
to detect survivin antibody and the incubation at room
temperature lasted for 45 min. Finally, the signals were
visualized by incubating sections with liquid DAB ?
(diaminobenzidine) (Dako) before counterstaining those
sections with hematoxylin. A colon carcinoma specimen
was used as a positive control. The substitution of survivin
antibody with normal goat serum was treated as the neg-
ative control. The results were evaluated by Dr. KW Chan,
a qualified pathologist, under light microscope. For each
section, the expression of survivin was categorized
according to the percentage of cancer cells stained positive
with survivin antibody (with score from 0 to 4; 0 B 5 %,
1 = 6–25 %, 2 = 26–50 %, 3 = 51–75 %, 4 C 75 %) and
the intensities of the signals (1?, 2? and 3?). Then, a
weighted index score (0–12) for each specimen was cal-
culated by multiplying the values of these two categories
[34], such that the tumors were segregated into two groups
based on the expression of survivin, that is, low expression
group (weighted index score 0–6) and high expression
group (weighted index score 7–12).
Statistical analysis
Data in the bar chart were expressed as mean ± SEM.
Either Pearson’s chi-squared test or Fisher’s exact test,
where appropriate, was used to assess the correlations for
clinical analysis and immunohistochemistry. Kaplan–
Meier method was employed for survival analysis, and the
differences in survival were estimated using log-rank test.
A p value of less than 0.05 was considered statistically
significant. All the statistical analyzes were performed
using SPSS 12.0 for Windows (Chicago, IL, USA).
Results
High expression of survivin in ESCC tissues and cell
lines
Up-regulation of survivin mRNA was demonstrated in
70 % (7 of 10) ESCC tissues when compared to their
adjacent non-tumor tissues. The increase in expression
ranged from *twofold (patient 7) to *16-fold (patient 6).
ESCC tissues from patient 5 and 8 showed down-regulation
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Fig. 2 High mRNA expression of survivin in esophageal squamous
cell carcinoma (ESCC) cell lines. Quantitative polymerase chain
reaction (qPCR) was performed to examine the mRNA expression of
survivin in 5 ESCC cell lines (HKESC-1, HKESC-2, HKESC-3,
HKESC-4, and SLMT-1) and a non-neoplastic esophageal epithelial
cell line NE-1. The relative expression of survivin in ESCC cell lines
was compared to the NE-1 cell line and is represented as a relative
fold ratio. High expression of survivin mRNA was associated with
ESCC cells when compared to the NE-1 cells. The fold ratio of NE-1
cell line is arbitrarily set to 1 and the fold ratio of each ESCC cell line
versus NE-1 cell line is indicated above the bar for each cell line.
Each sample was performed in at least duplicate
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of survivin mRNA compared with the adjacent non-tumor
tissues. ESCC tissue from patient 9 had no apparent dif-
ference in the expression of survivin (Fig. 1). Five human
ESCC cell lines and a non-neoplastic esophageal epithelial
cell line were used to study the expression of survivin. The
mRNA expression of survivin in all ESCC cell lines
(HKESC-1, HKESC-2, HKESC-3, HKESC-4, and SLMT-1)
was higher than that of non-neoplastic NE-1 cell line. In
particular, HKESC-3, HKESC-4, and SLMT-1 cells dem-
onstrated *50-fold increase in survivin mRNA when
compared to NE-1 cells (Fig. 2). Similar observation was
found in the protein level of survivin in this panel of cell
lines, such that high expression of survivin protein was
observed in ESCC cells when compared to NE-1 cells
having non-detectable level of survivin (Fig. 3).
High nuclear survivin indicates ESCC patients
in early-stage and without nodal metastasis
Immunohistochemistry was performed to reveal the local-
ization of survivin in 64 tumor tissues of ESCC patients
and 10 randomly selected adjacent non-tumor tissues from
the same patient cohort. Positive control experiment
showed staining of nuclear survivin, while negative control
had no staining of survivin (data not shown). For both
tumor and non-tumor tissues, survivin was found at the cell
nuclei in all specimens examined (Fig. 4). Nuclear survivin
was found in majority of cancer cells in ESCC tissues
(Fig. 4a), while it was associated preferentially in the
proliferating layer of the epithelium and not found in the
upper and more differentiated layer in the non-tumor tis-
sues (Fig. 4b).
When we correlated the expression of nuclear survivin
with different clinicopathological parameters of ESCC
patients, nuclear expression of survivin was inversely
associated with the likelihood of developing nodal metas-
tasis (p = 0.021). ESCC patients having high expression of
nuclear survivin were less likely to develop nodal metastasis
when compared to those patients with low expression of
nuclear survivin. Nuclear survivin was also significantly
associated with early-stage ESCC (p = 0.039), which
means ESCC patients with high level of nuclear survivin
were more likely to be in the early-stage of disease
(Table 2). In addition to tumor stage, R category of resec-
tion is another prognostic parameter for ESCC patients;
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Fig. 3 High protein level of survivin in esophageal squamous cell
carcinoma (ESCC) cell lines. Western blot was performed to examine
the protein level of survivin in ESCC cell lines (HKESC-1, HKESC-
2, HKESC-3, HKESC-4, and SLMT-1) and a non-neoplastic esoph-
ageal epithelial cell line NE-1. High protein level of survivin was
found in ESCC cells when compared to the NE-1 cells. This figure
shows the representative image from several experiments
Fig. 4 Nuclear localization of survivin in esophageal squamous cell
carcinoma (ESCC) and non-tumor tissues. Immunohistochemistry
was performed to study the localization of survivin in tumor
(a) (n = 64) and non-tumor (b) (n = 10) tissues of ESCC patients.
Intense staining of survivin was found in the cell nucleus of each
specimen studied. Representative images are shown here. Original
magnification, 9200
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however, no correlation was found between the expression
of nuclear survivin and this factor. ESCC patients having
high or low expression of nuclear survivin had a median
survival of 17.90 months (95 % CI: 4.67–31.13 months)
and 14.75 months (95 % CI: 12.84–16.67 months),
respectively. There was no statistically significant differ-
ence (p = 0.339) in the survival of patients having different
expression of nuclear survivin (data not shown).
Discussion
This is the first report showing the correlations between
nuclear survivin expression with nodal metastasis and
pathological stage in ESCC patients. ESCC patients with
high expression of nuclear survivin are mostly in early-
stage of disease without nodal metastasis. In the literatures,
there are conflicting results in the prognostic significance
of survivin in ESCC. This may partly due to the different
experimental methods used like immunohistochemistry and
qPCR [2, 3, 35–40]. For instance, immunohistochemical
studies have demonstrated significant correlation between
nuclear survivin and poor prognosis of ESCC patients [35,
37]. On the contrary, Warnecke-Eberz and colleagues have
suggested survivin mRNA as a favorable marker for ESCC
based on their results derived from transcriptional studies
[39]. However, there has been no immunohistochemical
study thus far reporting on any positive effect of nuclear
survivin in ESCC patients.
In early findings, survivin expression is connected to
microvessel density [16]. Tumors with high capacity of
microvessel have been shown to have high metastatic
potential [41, 42]. In this report, high nuclear survivin
expression may suggest retaining of survivin protein inside
the nucleus, diminishing the effect of microvessel forma-
tion in the tumor and thus relating to the less likelihood of
nodal metastases in ESCC.
Survivin is proposed to inhibit apoptosis after its phos-
phorylation by p34cdc2/cyclin B complex, while a survivin
mutant (with mutation at alanine, T34A), which is not able
to undergo phosphorylation, can induce apoptosis probably
by substrate competition [4]. As different post-translational
modifications could affect epitope accessibility of nuclear
and cytoplasmic survivin, it is postulated that only cyto-
plasmic survivin can associate with and be phosphorylated
by p34cdc2/cyclin B complex. On the other hand, nuclear
survivin that remains unphosphorylated even in the presence
of p34cdc2/cyclin B complex always favors and triggers
apoptosis. Therefore, this helps to explain the different
prognostic implications of cytoplasmic and nuclear survivin
in cancers because of their different roles. Cells expressing
survivin with mutation at nuclear exportation signal (NES)
accumulated in the nucleus, and these cells demonstrated
reduced cytoprotective capabilities because of the inability
of these survivin mutants in protecting cells against
X-irradiation and TNF-related apoptosis-inducing ligand
(TRAIL)-induced apoptosis [5]. It is obvious that nuclear
survivin has impaired cytoprotective functions [6, 7].
The survivin antibody we used in this study can recognize
all splice variants of survivin, including survivin-2b for
which this variant has proven pro-apoptotic effect by acting
as a natural antagonist of anti-apoptotic survivin in tumor
cells [8, 43, 44]. Suga et al. [45] found that colorectal car-
cinoma patients having a higher mRNA expression ratio of
survivin-2b/wild-type survivin were associated with better
prognosis and in early-stage disease, while patients with a
lower expression of this ratio had shorter survival and
advanced stage disease. Regarding the cellular level of sur-
vivin-2b, its expression was higher in less aggressive
Table 2 Correlation of nuclear survivin with various clinicopatho-
logical parameters in esophageal squamous cell carcinoma patients
Clinicopathological
parameters
Subgroups Low
expression
of nuclear
survivin
High
expression
of nuclear
survivin
p value
Age (grouped) Below or
equal 65
14 17 0.617
Above 65 18 15
Gender Female 9 8 1.000
Male 23 24
Smoking Non
smoker
15 16 1.000
Smoker 17 16
Level of tumor Upper 5 5 0.346
Middle 18 19
Lower 6 8
Double 3 0
Tumor
differentiation
Poor 8 6 0.822
Moderate 18 20
Well 6 6
R category R0 25 20 0.274
R1/R2 7 12
T-stage Early
(T1/T2)
5 8 0.536
Advanced
(T3/T4)
27 24
N-stage N0 8 18 0.021
N1 24 14
M-stage M0 27 31 0.196
M1a/M1b 5 1
Overall pathological
stage
Early
(stage
I/II)
8 17 0.039
Advanced
(stage
III/IV)
24 15
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neuroblastoma and benign brain tumors when compared to
their corresponding more aggressive types [46, 47]. Fur-
thermore, Mahotka et al. [48] also observed a significant
decrease in survivin-2b level during the progression of renal
cell carcinoma. All these findings prove for the inhibitory
role of survivin-2b in cancer development. Indeed, the cel-
lular localizations of survivin-2b among different cell types
are still under debate [44]. It is believed that the positive
stains of nuclear survivin in ESCC tissues may also
encompass survivin-2b, which is probably responsible for
pro-apoptotic process that is observed in less aggressive
tumor condition. Future work should be done to focus on
studying the presence of survivin-2b in ESCC tissues.
In conclusion, we have shown for the first time in this
study that up-regulation of nuclear survivin correlated with
earlier pathological stage and less likelihood of nodal
metastases in ESCC. This may be helpful in further dis-
secting the debate regarding the role of survivin as a
prognostic marker in ESCC.
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